CA199、CA50联检对胰腺癌的诊断价值

目的：探讨糖类抗原CA199及CA50联合检测对胰腺癌诊断的临床价值及预后分析。方法：用放射免疫分析法检测30例健康者，20例慢性胰腺炎及40例胰腺癌术前患者血清中CA199及CA50的含量。结果：胰腺癌患者术前血清CA199及CA50值均明显高于正常组及慢性胰腺炎组，两者比较有显著性差异（P＜0．01），CA199及CA50两者联合检测较单测任何一项其灵敏度、特异性及准确性均有提高。胰腺癌伴有淋巴结转移的患者血清CA199及CA50值较淋巴结无转移者亦增高（P＜0．05），其阳性率亦高于无淋巴结转移者。结论：CA199及CA50联合检测可提高胰腺癌诊断的灵敏度、特异性及准确性，胰腺癌患者血清CA199及CA50含量变化有助于预测胰腺癌有无转移及复发，是进行疗效观察的参考指标。

Clinical Analysis of the Value of Combined Detection of Serum CA199 and CA50 Levels in Patients with Pancreatic Cancer

Objective To investigate the clinical value of combined test of serum CA 199 and CA 50 levels in thd diagnosis and prognosis of patients with pancreatic cancer. Methods Serum levels of CA 199 and CA 50 in 40 cases of pancreatic cancer, 20 cases of chronic pancreatitis and 30 normal controls were detected by radioimmunoassay. Results Serum CA 199 and CA 50 levels in pancreatic cancer patients were significantly higher than those in normal controls and chronic pancreatitis patients ( P <0.01). If serum CA 199 and CA 50 were detected simultaneously, the sensitivity, specificity and accuracy of diagnosis of pancreatic cancer could be improved. Serum CA 199 and CA 50 levels in cancer patients with lymph node matastasis were much higher than those without lymph node matastasis ( P <0.05). Conclusion Serum CA 199 and CA 50 detected simultaneously couid improve the sensitivity and accuracy in diagonosis of pancreatic cancer. The changes of serum CA 199 and CA 50 level were helpful to predit whether matastasis or recurrence had occurred.